Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

What happened

Autolus Therapeutics granted 15 employees stock options for 75,400 American Depositary Shares and 129,310 restricted stock units under its 2025 Inducement Plan. The awards, dated October 21, 2026, used a $1.66 exercise price, equal to the October 20, 2026 closing price, under Nasdaq Listing Rule 5635(c)(4).

Confirmed

Global impact / market context

These grants tie new hires' pay to Autolus's share price, which means employees gain only if the stock rises above $1.66. That can help retain staff at a commercial-stage biotech company, but it also creates future dilution, which means existing shareholders' ownership stakes shrink as options and RSUs convert into shares.

Analyst inference

Inducement grants are routine for newly public or growing companies hiring talent, and Nasdaq's rule allows them without a shareholder vote. The $1.66 exercise price, matching the recent closing price, suggests the stock traded near that level, but the article gives no trading reaction or investor positioning details.

Analyst inference

What to watch

1. The options vest 25% on the one-year anniversary of each employee's hire date, with the rest vesting in 36 equal monthly installments; RSUs vest in four equal annual installments, all requiring continued service. Confirmed
2. Watch whether Autolus files further inducement grants under its 2025 Inducement Plan, since repeated awards would increase the total shares reserved for employees and the potential dilution, which means the reduction in each existing holder's ownership share, over time. Proposed
3. Track Autolus's share count and dilution disclosures in future filings, because converting these options and RSUs into ordinary shares raises the share count and can lower reported earnings per share, which means profit attributed to each share. Analyst inference

Evidence

• globenewswire.com